Structure-activity relationships in 1,4-benzodioxan-related compounds. 8. {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of α1D- and α1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7750-7763

  Quaglia, Wilma ^a   Santoni, Giorgio ^a   Pigini, Maria ^a   Piergentili, Alessandro ^a   Gentili, Francesco ^a   Buccioni, Michela ^a   Mosca, Michela ^a   Lucciarini, Roberta ^a   Amantini, Consuelo ^a   Nabissi, Massimo Ivan ^a   Ballarini, Patrizia ^a   Poggesi, Elena ^b   Leonardi, Amedeo ^b   Giannella, Mario ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b Recordati S p A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZODIOXAN DERIVATIVE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (2 METHYLBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (2 NITROBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (3 METHOXYBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (3 METHYLBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (3 NITROBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (4 ETHOXYBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (4 ISOPROPOXYBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (4 METHOXYBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (4 METHYLBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 (2,6 DIMETHOXYPHENOXY)ETHYL] [2 [2 (4 NITROBENZYLOXY)PHENOXY]ETHYL]AMINE; [2 [2 (3 CHLOROBENZYLOXY)PHENOXY]ETHYL] [2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINE; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPENPHENDIOXAN; NORADRENALIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL STRAIN PC 3; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LC 50; PROSTATE CANCER; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PHENYL ETHERS; PROSTATIC NEOPLASMS; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28144446782     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0580398     Document Type: Article

References (55)

1. For part 7, see ref 41.
2. (a) Calzada, B. C.; De Artinano A. A. α-Adrenoceptors Subtypes. Pharmacol. Res. 2001, 44, 195-208.
3. 1-Adrenergic Receptors: New Insights and Directions. J. Pharmacol. Exp. Ther. 2001, 298, 403-410.
4. 1L-Adrenoceptor Pharmacology in Functional Studies. Eur. J. Pharmacol. 1999, 370, 337-343.
5. 1-Adrenergic Receptor Subtypes in Human Prostate. J. Urol. 1993, 150, 546-551.
6. 1D- Adrenoceptors in Hyperplastic and Non-Hyperplastic Human Prostate. J. Urol. 1999, 161, 635-640.
7. 1C- Adrenoceptor in Human Prostate: Cloning, Functional Expression, and Localization to Specific Prostate Cell Types. Br. J. Pharmacol. 1995, 115, 1475-1485.
8. 1- Adrenoceptor Subtypes in Human Hypertrophied Prostate by in Situ Hybridization. Histochem. J. 1996, 28, 283-288.
9. 1-Adrenergic Receptors Activate Ca(2+)-Permeable Cationic Channels in Prostate Cancer Epithelial Cells. J. Clin. Invest. 2003, 111, 1691-1701.
10. 1-Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis. Cancer Res. 2000, 60, 4550-4555.
11. (a) Caine, M. α-Adrenergic Blockers for the Treatment of Benign Prostatic Hyperplasia. Urol. Clin. North Am. 1990, 17, 641-649.
12. (b) Thorpe, A.; Neal, D. Benign Prostatic Hyperplasia. Lancet 2003, 361, 1359-1367.
13. 1-Adrenoceptor-Independent Action. Cancer Res. 2002, 62, 597-602.
14. Yang, G.; Timme, T. L.; Park, S. H.; Wu, X.; Wyllie, M. G.; Thompson, T. C. Transforming Growth Factor beta 1 Transduced Mouse Prostate Reconstitutions: II. Induction of Apoptosis by Doxazosin. Prostate 1997, 33, 157-163.
15. 1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis via TGF-beta Signalling and I kappa B alpha Induction. Br. J. Cancer 2003, 88, 1615-1621.
16. Dizeyi, N.; Bjartell, A.; Nilsson, E.; Hansson, J.; Gadaleanu, V.; Cross, N.; Abrahamsson, P. A. Expression of Serotonin Receptors and Role of Serotonin in Human Prostate Cancer Tissue and Cell Lines. Prostate 2004, 59, 328-336.
17. 1-Adrenoceptor Antagonists in Prostate Cancer Cells: Antagonistic Effect of bcl-2. J. Urol. 2003, 169, 1150-1156.
18. 1-Adrenoceptor Antagonist Terazosin Induces Prostate Cancer Cell Death through a p53 and Rb Independent Pathway. Oncol. Rep. 2003, 10, 1555-1560.
19. Zeng, L.; Rowland, R. G.; Lele, S. M.; Kyprianou, N. Apoptosis Incidence and Protein Expression of p53, TGF-beta Receptor II, p27Kip1, and Smad4 in Benign, Premalignant, and Malignant Human Prostate. Hum. Pathol. 2004, 35, 290-297.
20. Noveral, J. P.; Grunstein, M. M. Adrenergic Receptor-Mediated Regulation of Cultured Rabbit Airway Smooth Muscle Cell Proliferation. Am. J. Physiol. 1994, 267, 291-299.
21. 1-Adrenergic Agonists of the Progression Phase in the Proliferation of Primary Cultures of Smooth Muscle Cells in Mouse and Rat Aorta. Biol. Pharm. Bull. 1995, 18, 1373-1376.
22. 1B-Adrenergic Receptors in HEK293 Cells. Acta Pharmacol. Sin. 2000, 21, 55-59.
23. McVary, K. T.; McKenna, K.E.; Lee, C. Prostate Innervation. Prostate Suppl. 1998, 8, 2-13.
24. 1D- Adrenergic Receptors and Mitogen-Activated Protein Kinase Mediate Increased Protein Synthesis by Arterial Smooth Muscle. Mol. Pharmacol. 1997, 51, 764-775.
25. Kanagawa, K.; Sugimura, K.; Kuratsukuri, K.; Ikemoto, S.; Kishimoto, T.; Nakatani, T. Norepinephrine Activates P44 and P42 MAPK in Human Prostate Stromal and Smooth Muscle Cells but not in Epithelial Cells. Prostate 2003, 56, 313-318.
26. 1-Adrenoceptor Blocking Effects of a New Benzodioxane. J. Pharm. Pharmacol. 1975, 27, 295-296.
27. 1-Adrenoreceptor Antagonists. J. Med. Chem. 1990, 33, 2946-2948.
28. Quaglia, W.; Pigini, M.; Tayebati, S. K.; Piergentili, A.; Giannella, M.; Marucci, G.; Melchiorre, C. Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 4. Effect of Aryl and Alkyl Substituents at Position 3 on α-Adrenoreceptor Blocking Activity. J. Med. Chem. 1993, 36, 1520-1528.
29. 1-Adrenoreceptor Subtypes. J. Med. Chem. 1999, 42, 2961-2968.
30. 1-Adrenergic Receptor Subtype-Selective Antagonist Binding. Mol. Pharmacol. 1996, 50, 1118-1126.
31. 1A- Adrenergic Receptor Determines Subtype Selectivity of Dihydropyridine Antagonists. Biochemistry 1996, 35, 14312-14317.
32. Topliss J. G. Utilization of Operational Schemes for Analogue Synthesis in Drug Design. J. Med. Chem. 1972, 15, 1006-1011.
33. Topliss J. G. A Manual Method for Applying the Hansch Approach to Drug Design. J. Med. Chem. 1977, 20, 463-469.
34. 1-Adrenoceptor Antagonist Terazosin. Prostate 2001, 48, 71-78.
35. Woolley, D. W. Probable Evolutionary Relations of Serotonin and Indole-Acetic Acid, and Some Practical Consequences Therefrom. Nature (London) 1957, 180, 630-633.
36. 1B-Adrenoceptors. Drug Dev. Res. 1998, 44, 140-162.
37. 1-Adrenoceptor Antagonist. Pharmacol Commun. 1995, 6, 79-86.
38. 1A Receptor. Nature 1988, 335, 358-360.
39. 1A Receptor. J. Biol. Chem. 1989, 284, 14848-14852.
40. 1A-Adrenoreceptors. Eur. J. Pharmacol. 1991, 202, 33-44.
41. 1D-Adrenoreceptor Antagonist, Isolated from Fissistigma glaucescens. Br. J. Pharmacol. 1994, 112, 1174-1180.
42. 1D Subtype. Eur. J. Pharmacol. 1996, 297, 241-248.
43. van Rossum, J. M. Cumulative Dose-Response Curves. II. Technique for the Making of Dose-Response Curves in Isolated Organs and the Evaluation of Drug Parameters. Arch. Int. Pharmacodyn. Ther. 1963, 143, 299-330.
44. 35S]GTPγS Binding. Eur. J. Pharmacol. 1997, 320, 267-275.
45. 1-Adrenoreceptor Subtypes. J. Med. Chem. 2002, 45, 1633-1643.
46. Cal, C.; Uslu, R.; Gunaydin, G.; Ozyurt, C.; Omay, S. B. Doxazosin: a New Cytotoxic Agent for Prostate Cancer? BJU Int. 2000, 85, 672-675.
47. Grever, M. R.; Shepartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin. Oncol. 1992, 19, 622-638.
48. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A Novel Assay for Apoptosis. Flow Cytometric Detection of Phosphatidylserine Expression on Early Apoptotic Cells Using Fluorescein Labelled Annexin V. J. Immunol. Methods 1995, 184, 39-51.
49. Lindquist, J. M.; Rehnmark, S. Ambient Temperature Regulation of Apoptosis in Brown Adipose Tissue. Erk1/2 Promotes Norepinephrine-Dependent Cell Survival. J. Biol. Chem. 1998, 273, 30147-30156.
50. Noh, J. S.; Kim, E. Y.; Kang, J. S.; Kim, H. R.; Oh, Y. J.; Gwag, B. J. Neurotoxic and Neuroprotective Actions of Catecholamines in Cortical Neurons. Exp. Neurol. 1999, 159, 217-224.
51. Popovik, E.; Haynes, L. W. Survival and Mitogenesis of Neuroepithelial Cells Are Influenced by Noradrenergic but not Cholinergic Innervation in Culture Embryonic Rat Neopallium. Brain Res. 2000, 853, 227-235.
52. 1D-Adrenoceptor: Molecular and Cellular Characteristics and Integrative Roles. Eur. J. Pharmacol. 2004, 500, 113-120.
53. 1D-Adrenoceptor Phosphorylation and Desensitization. Biochem. Pharmacol. 2004, 67, 1853-1858.
54. 1B-Adrenergic Receptors. J. Biol. Chem. 2004, 279, 15541-15549.
55. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.